EGFR and hepatocellular carcinoma: For example in HCC, METTL1 expression promotes tumor resistance to both radiotherapy (80) and the tyrosine kinase inhibitor levatinib (81), enhancing the translation of the DNA double-strand break (DSB) repair enzyme DNA ligase IV or components of the EGFR pathway, respectively.